Literature DB >> 25054901

Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches.

Rimas V Lukas1, Maciej S Lesniak, Ravi Salgia.   

Abstract

Non-small-cell lung cancer (NSCLC) patients experience a high incidence of brain metastases, de novo and recurrent. We review the mechanisms of brain metastases and promising NSCLC molecular markers to delineate potential future therapeutic targets. Discussed are the current and previously utilized roles of surgery, radiation (both therapeutic and prophylactic), and systemic therapies in the treatment of NSCLC brain metastases. Future directions for treatment of NSCLC brain metastases will conclude our review.

Entities:  

Mesh：

Year:  2014        PMID： 25054901      PMCID： PMC6128200          DOI： 10.2217/cns.13.66

Source DB:  PubMed          Journal:  CNS Oncol        ISSN： 2045-0907


  101 in total

1.  Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: a multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603).

Authors:  D Galetta; V Gebbia; N Silvestris; F Ferraù; F Carrozza; S Cigolari; P Russo; F Calista; V Adamo; G Colucci
Journal:  Lung Cancer       Date:  2010-08-21       Impact factor: 5.705

2.  Stereotactic radiosurgery plus whole-brain radiotherapy for treatment of multiple metastases from non-small cell lung cancer.

Authors:  G Minniti; M Salvati; R Muni; G Lanzetta; M F Osti; E Clarke; A Costa; A Bozzao; G Trasimeni; R Maurizi Enrici
Journal:  Anticancer Res       Date:  2010-07       Impact factor: 2.480

Review 3.  Radiotherapy and radiosurgery for tumors of the central nervous system.

Authors:  John P Kirkpatrick; Fang-Fang Yin; John H Sampson
Journal:  Surg Oncol Clin N Am       Date:  2013-03-19       Impact factor: 3.495

4.  Weekly gemcitabine as a radiosensitiser for the treatment of brain metastases in patients with non-small cell lung cancer: phase I trial.

Authors:  Yu-juan Huang; Yi-long Wu; Song-xi Xie; Jing-ji Yang; Yi-sheng Huang; Ri-qiang Liao
Journal:  Chin Med J (Engl)       Date:  2007-03-20       Impact factor: 2.628

5.  Interim data from the Medical Research Council QUARTZ Trial: does whole brain radiotherapy affect the survival and quality of life of patients with brain metastases from non-small cell lung cancer?

Authors:  R E Langley; R J Stephens; M Nankivell; C Pugh; B Moore; N Navani; P Wilson; C Faivre-Finn; R Barton; M K B Parmar; P M Mulvenna
Journal:  Clin Oncol (R Coll Radiol)       Date:  2012-12-02       Impact factor: 4.126

6.  Increased expression of integrin alpha3beta1 in highly brain metastatic subclone of a human non-small cell lung cancer cell line.

Authors:  Tatsuya Yoshimasu; Teruhisa Sakurai; Shoji Oura; Issei Hirai; Hirokazu Tanino; Yozo Kokawa; Yasuaki Naito; Yoshitaka Okamura; Ichiro Ota; Naoyuki Tani; Nariaki Matsuura
Journal:  Cancer Sci       Date:  2004-02       Impact factor: 6.716

7.  Predicting tumor control after resection bed radiosurgery of brain metastases.

Authors:  Neal Luther; Douglas Kondziolka; Hideyuki Kano; Seyed H Mousavi; Johnathan A Engh; Ajay Niranjan; John C Flickinger; L Dade Lunsford
Journal:  Neurosurgery       Date:  2013-12       Impact factor: 4.654

8.  Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain.

Authors:  Mihaela Lorger; Joseph S Krueger; Melissa O'Neal; Karin Staflin; Brunhilde Felding-Habermann
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-16       Impact factor: 11.205

9.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors:  D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316

Review 10.  Role of stereotactic radiosurgery in patients with more than four brain metastases.

Authors:  Vikram Jairam; Veronica L S Chiang; James B Yu; Jonathan P S Knisely
Journal:  CNS Oncol       Date:  2013-03
View more
  4 in total

Review 1.  Brain metastases: an overview.

Authors:  F Bertolini; A Spallanzani; A Fontana; R Depenni; G Luppi
Journal:  CNS Oncol       Date:  2015

2.  Role of perilesional edema and tumor volume in the prognosis of non-small cell lung cancer (NSCLC) undergoing radiosurgery (SRS) for brain metastases.

Authors:  Valerio Nardone; Sara Nanni; Pierpaolo Pastina; Claudia Vinciguerra; Alfonso Cerase; Pierpaolo Correale; Cesare Guida; Antonio Giordano; Paolo Tini; Alfonso Reginelli; Salvatore Cappabianca; Luigi Pirtoli
Journal:  Strahlenther Onkol       Date:  2019-05-23       Impact factor: 3.621

3.  Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

Authors:  Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Jürgen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Santosh Sutradhar; Siyu Li; Tomasz Szczudlo; Alejandro Yovine; Alice T Shaw
Journal:  Lancet Oncol       Date:  2016-03-11       Impact factor: 41.316

Review 4.  State-of-the-art considerations in small cell lung cancer brain metastases.

Authors:  Rimas V Lukas; Vinai Gondi; David O Kamson; Priya Kumthekar; Ravi Salgia
Journal:  Oncotarget       Date:  2017-07-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.